All studies
RecruitingPHASE2INTERVENTIONAL

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

This study is looking at a new medicine called RPT904 for people aged 12 to 55 who have allergies to common foods like peanuts, milk, eggs, cashews, or walnuts. RPT904 is a long-acting antibody that might reduce allergic reactions. Participants will receive either RPT904 or a dummy medicine (placebo) for over a year. The main goal is to find out if RPT904 helps people tolerate more of their problem food without allergic reactions during a controlled food test. The study will also carefully watch for any side effects. Regular study visits will be needed. Participants would be in the study for about 68 to 74 weeks in total.

At a glance

Status
Recruiting
Phase
PHASE2
Sponsor
RAPT Therapeutics, Inc.
Enrolment target
100
Start
22 Oct 2025
Estimated completion
01 Jan 2028

What is this study about?

This study is a research project looking into a new medicine called RPT904 for people who have food allergies. The main idea behind RPT904 is that it's a special type of antibody, like tiny helpers in your body, designed to block the things that cause allergic reactions. The hope is that by taking RPT904, people with allergies might become less sensitive to certain foods.

The study wants to find out two main things. First, does RPT904 help people become more tolerant to the foods they are allergic to? This means could they eat more of that food without having an allergic reaction? To check this, participants will have carefully supervised food challenges. Second, the study will closely monitor the medicine to make sure it's safe and to understand any side effects it might have. This is a "Phase 2b" study, which means it's one of the earlier stages of testing in humans, following initial safety checks, to see how well the medicine works and find the best dose.

Taking part in a study like this is important because it helps scientists learn more about new treatments for conditions like food allergies. If RPT904 proves to be safe and effective, it could offer a new way to manage food allergies in the future, potentially improving the quality of life for many people.

Key takeaways

  • Tests a new medicine (RPT904) for food allergies.
  • Aimed at people aged 12 to 55 with specific food allergies.
  • Compares RPT904 to a dummy medicine (placebo).
  • Checks if RPT904 helps you eat more of your problem food safely.
  • Monitors for safety and side effects.
  • Participation lasts about 68-74 weeks with regular clinic visits.

Who may be eligible?

To join this study, you need to be aged between 12 and 55 years old.

You must have a confirmed allergy to at least one of these foods: peanuts, milk, eggs, cashews, or walnuts. This allergy will need to be proven through specific tests, including skin prick tests, blood tests for allergy markers (IgE), and a controlled food challenge where you eat a small amount of the food under medical supervision to confirm an allergic reaction.

It's also important that you (or your parent/guardian if you're under 18) can understand what the study involves and agree to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 12 and 55 years old?
  2. Do you have a confirmed allergy to at least one of these foods: peanut, milk, egg, cashew, or walnut?
  3. Are you able to attend regular clinic appointments for over a year?
  4. Are you able to understand and agree to the study procedures (or is your parent/guardian able to)?
  5. Are you willing to undergo supervised food challenges?
Answer every question to see your result.

What does participation involve?

If you join this study, you'll be in it for about 68 to 74 weeks, which is roughly a year and a half. During this time, you'll receive either the new medicine, RPT904, or a dummy medicine (called a placebo). For the first 24 weeks, you'll be given either the real medicine or the placebo. After that, if you were on the placebo, you'll switch to the real medicine. The medicine will be given as injections every 8 or 12 weeks, with an extra starting dose at certain points.

You'll need to attend clinic visits every 2 to 6 weeks throughout the entire study to help the study team monitor your health and how you're responding. These visits are important to make sure everyone involved in the study doesn't know who is getting the real medicine and who is getting the placebo. There will also be food tests, where you'll carefully eat tiny amounts of the food you're allergic to, to see how the medicine is working. The study team will be watching closely for any allergic reactions and side effects during these tests and throughout your time in the study.

Potential risks and benefits

Taking part in a study like this could potentially offer benefits, such as helping you safely tolerate more of the food you're allergic to, or gaining access to a new treatment option before it's widely available. However, there are also potential risks; for example, the medicine might cause side effects, or it might not work for everyone. During the food challenges, there's a risk of having an allergic reaction, which will be managed by the study team. You will be closely monitored, and your safety is the top priority. Remember, joining a clinical study is always voluntary, and you have the right to withdraw at any time, for any reason, without affecting your medical care.

Locations (31)

  • Arkansas Children's
    Verified postcode
    Little Rock, United States· Recruiting
  • Sean N. Parker Center for Allergy and Asthma Research
    Verified postcode
    Palo Alto, United States· Recruiting
  • Asthma & Allergy Associates, P.C.
    Verified postcode
    Colorado Springs, United States· Recruiting
  • National Jewish Health
    Verified postcode
    Denver, United States· Recruiting
  • Children's National Hospital
    Verified postcode
    Washington D.C., United States· Recruiting
  • University of South Florida
    Verified postcode
    Tampa, United States· Recruiting
  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics
    Verified postcode
    Atlanta, United States· Recruiting
  • Boston's Children's Hospital
    Verified postcode
    Boston, United States· Recruiting
  • University of Michigan
    Verified postcode
    Ann Arbor, United States· Recruiting
  • Clinical Research Institute, Inc
    Verified postcode
    Minneapolis, United States· Recruiting
  • Northwell Health
    Verified postcode
    Great Neck, United States· Recruiting
  • Icahn School of Medicine at Mount Sinai
    Verified postcode
    New York, United States· Recruiting

Common questions

What is RPT904?

RPT904 is a new medicine being tested. It's a type of antibody designed to help reduce allergic reactions in people with food allergies.

What is a 'placebo'?

A placebo is a dummy treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the real medicine's effects.

How long does the study last?

Each person will be part of the study for about 68 to 74 weeks, which is roughly a year and a half.

What kind of food allergies are included?

The study includes allergies to peanuts, milk, eggs, cashews, and walnuts.

Will I know if I'm getting the real medicine or the placebo?

No, neither you nor the study team will know who is receiving the real medicine (RPT904) or the placebo during the initial part of the study. This is called 'double-blinded'.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Phase 2b Study of RPT904 as Monotherapy in Participants With…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.